Obesity is a significant public health concern in the G7 countries and is growing as an epidemic. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Compounding this problem is the fact that available treatments do not have desirable risk-benefit profiles at low prices; in addition, few novel agents are in development for obesity. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. However, with the prevalence of obesity, even if such an agent is developed and approved, payers will likely need to restrict its access to limit the impact on finite healthcare budgets.
Which metabolic and central pathways have high potential as drug targets?
What is the prevalence of obesity in the major pharmaceutical markets under study?
How is obesity currently treated? What do experts think about Novo Nordisk’s Saxenda as a treatment for obese / overweight patients?
What is the current level of unmet need according to obesity experts? How will this need be addressed over the 2020-2030 forecast period?
What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
How will the obesity market evolve over the next 10 years?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with thought-leading endocrinologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Prevalence of obesity and drug-treatable overweight by country, including diagnosed and drug-treated populations.
Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
Market forecast features: 10-year, annualized, drug-level sales and patient share of key obesity therapies through 2030, segmented by brands / generics and epidemiological subpopulations.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.